Cullinan Management, Inc. launches an IPO.

IPO of Cullinan Management, Inc. (CGEM) will take place on January 7, 2021. Cullinan is a biopharmaceutical company specializing in the development of a diversified pipeline of targeted oncology and immuno-oncology therapies for cancer patients. The lead candidate of the company, CLN-081, is an orally available small molecule designed as a next generation irreversible epidermal growth factor receptor to selectively target cells.
The company currently has the worldwide development and commercialization rights for each of its therapeutic candidates, except for CLN-081 in Japan and Greater China (China, Hong Kong, Taiwan and Macau).
Listed underwriters of the IPO are Morgan Stanley, SVB Leerink and Evercore.